APEI Stock Analysis: American Public Education | NASDAQ
Education & Training Services | NASDAQ, USA | Market Cap: 1.069m USD | 12M Return: 86.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.1M
Qual. Beats: 3
Rev. Trend: 97.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
American Public Education, Inc. (APEI) is a US-based provider of online and campus-based postsecondary education, operating through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. The company offers 181 degree programs, 110 certificate programs, and four diploma programs spanning public service-oriented fields such as nursing, national security, military studies, intelligence, and homeland security, as well as traditional academic disciplines including business, health science, information technology, justice studies, education, and liberal arts.
APEI also delivers career learning and leadership training to the federal civilian workforce in person and online, and through Hondros College of Nursing provides pre-licensure nursing education, including a diploma in practical nursing, an associate degree in nursing, and a bachelor of science in nursing. The company is headquartered in Charles Town, West Virginia, was incorporated in 1991, and trades as a small-cap stock within the US for-profit Education Services sub-industry, a sector that historically serves a disproportionate share of military-affiliated and working-adult learners seeking flexible, career-oriented degree pathways.
- APUS military enrollment growth drives segment revenue
- Title IV and GI Bill funding regulations impact federal aid dependence
- Rasmussen University and Hondros nursing enrollment trends shape margins
| Net Income: 40.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 5.70 > 1.0 |
| NWC/Revenue: 28.46% < 20% (prev 29.79%; Δ -1.33% < -1%) |
| CFO/TA 0.16 > 3% & CFO 88.3m > Net Income 40.4m |
| Net Debt (-56.4m) to EBITDA (76.1m): -0.74 < 3 |
| Current Ratio: 2.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.8m) vs 12m ago 2.10% < -2% |
| Gross Margin: 53.72% > 18% (prev 53.01%; Δ 0.71% > 0.5%) |
| Asset Turnover: 118.0% > 50% (prev 109.7%; Δ 8.37% > 0%) |
| Interest Coverage Ratio: 14.69 > 6 (EBIT TTM 59.7m / Interest Expense TTM 4.07m) |
| A: 0.35 (Total Current Assets 282.1m - Total Current Liabilities 94.5m) / Total Assets 537.9m |
| B: 0.00 (Retained Earnings 231k / Total Assets 537.9m) |
| C: 0.11 (EBIT TTM 59.7m / Avg Total Assets 558.3m) |
| D: 1.32 (Book Value of Equity 306.2m / Total Liabilities 231.7m) |
| Altman-Z'' = 4.40 = AA |
| DSRI: 0.97 (Receivables 42.0m/41.9m, Revenue 659.0m/634.7m) |
| GMI: 0.99 (GM 53.01% / 53.72%) |
| AQI: 1.01 (AQ_t 0.25 / AQ_t-1 0.24) |
| SGI: 1.04 (Revenue 659.0m / 634.7m) |
| TATA: -0.09 (NI 40.4m - CFO 88.3m) / TA 537.9m) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of July 15, 2026, the stock is trading at USD 58.04 with a total of 216,007 shares traded. Over the past week, the price has changed by -2.19%, over one month by +12.24%, over three months by +1.26% and over the past year by +86.44%.
Current recommended Stop Loss: 53.20 (which is 8.3% or 2.2 ATR below the current price).
American Public Education has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy APEI.
- StrongBuy: 3
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 62.2 | 7.1% |
P/E Trailing = 30.1917
P/E Forward = 26.0417
P/S = 1.6218
P/B = 3.4906
P/EG = 1.7339
Revenue TTM = 659.0m USD
EBIT TTM = 59.7m USD
EBITDA TTM = 76.1m USD
Long Term Debt = 83.2m USD (from longTermDebt, last quarter)
Short Term Debt = 16.2m USD (from shortTermDebt, last quarter)
Debt = 164.6m USD (corrected: LT Debt 83.2m + ST Debt 16.2m) + Leases 65.2m
Net Debt = -56.4m USD (calculated: Debt 164.6m - CCE 221.0m)
Enterprise Value = 1.01b USD (1.07b + Debt 164.6m - CCE 221.0m)
Interest Coverage Ratio = 14.69 (Ebit TTM 59.7m / Interest Expense TTM 4.07m)
EV/FCF = 13.72x (Enterprise Value 1.01b / FCF TTM 73.8m)
FCF Yield = 7.29% (FCF TTM 73.8m / Enterprise Value 1.01b)
FCF Margin = 11.20% (FCF TTM 73.8m / Revenue TTM 659.0m)
Net Margin = 6.13% (Net Income TTM 40.4m / Revenue TTM 659.0m)
Gross Margin = 53.72% ((Revenue TTM 659.0m - Cost of Revenue TTM 305.0m) / Revenue TTM)
Gross Margin QoQ = 54.91% (prev 53.85%)
Tobins Q-Ratio = 1.88 (Enterprise Value 1.01b / Total Assets 537.9m)
Interest Expense / Debt = 2.47% (Interest Expense 4.07m / Debt 164.6m)
Taxrate = 21.70% (11.2m / 51.6m)
NOPAT = 46.8m (EBIT 59.7m * (1 - 21.70%))
Current Ratio = 2.98 (Total Current Assets 282.1m / Total Current Liabilities 94.5m)
Debt / Equity = 0.54 (Debt 164.6m / totalStockholderEquity, last quarter 306.2m)
Debt / EBITDA = -0.74 (Net Debt -56.4m / EBITDA 76.1m)
Debt / FCF = -0.76 (Net Debt -56.4m / FCF TTM 73.8m)
Total Stockholder Equity = 288.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.24% (Net Income 40.4m / Total Assets 537.9m)
RoE = 14.02% (Net Income TTM 40.4m / Total Stockholder Equity 288.1m)
RoCE = 16.09% (EBIT 59.7m / Capital Employed (Equity 288.1m + L.T.Debt 83.2m))
RoIC = 10.96% (NOPAT 46.8m / Invested Capital 426.7m)
WACC = 7.74% (E(1.07b)/V(1.23b) * Re(8.63%) + D(164.6m)/V(1.23b) * Rd(2.47%) * (1-Tc(0.22)))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.88 | Cagr: 2.22%
[DCF] Terminal Value 77.97% ; FCFF base≈62.8m ; Y1≈72.0m ; Y5≈106.0m
[DCF] Fair Price = 90.01 (EV 1.59b - Net Debt -56.4m = Equity 1.65b / Shares 18.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 3.27 | # QB: 3
Revenue Correlation: 97.44 | Revenue CAGR: 4.00% | SUE: 0.39 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.47 | Chg30d=-5.00% | Revisions=-25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.58 | Chg30d=-6.45% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=3.02 | Chg30d=+5.42% | Revisions=+40% | GrowthEPS=+37.5% | GrowthRev=+6.5%
EPS next Year (2027-12-31): EPS=3.77 | Chg30d=+0.94% | Revisions=+25% | GrowthEPS=+25.0% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +0% (up=3, down=3)